Browsing by Subject "Prostatic Neoplasms"
Now showing items 1-20 of 40
-
5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
(BMC Med, 2011-09-15)With the lifetime risk of being diagnosed with prostate cancer so great, an effective chemopreventive agent could have a profound impact on the lives of men. Despite decades of searching for such an agent, physicians still ... -
A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.
(Prostate cancer and prostatic diseases, 2019-09)<h4>Purpose</h4>The objective of this study was to test a low-carbohydrate diet (LCD) plus walking to reduce androgen deprivation therapy (ADT)-induced metabolic disturbances.<h4>Materials and methods</h4>This randomized ... -
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.
(Nature genetics, 2018-02)Lipids, either endogenously synthesized or exogenous, have been linked to human cancer. Here we found that PML is frequently co-deleted with PTEN in metastatic human prostate cancer (CaP). We demonstrated that conditional ... -
Association of LEP G2548A and LEPR Q223R polymorphisms with cancer susceptibility: evidence from a meta-analysis.
(PloS one, 2013-01)BACKGROUND: Numerous epidemiological studies have examined associations of genetic variations in LEP (G2548A, -2548 nucleotide upstream of the ATG start site) and LEPR (Q223R, nonsynonymous SNP in exon 6) with cancer ... -
Caring for Alaska Native prostate cancer survivors in primary care: a survey of Alaska Tribal Health System providers.
(Int J Circumpolar Health, 2014)BACKGROUND: Little is known about the constraints of optimizing health care for prostate cancer survivors in Alaska primary care. OBJECTIVE: To describe the experiences and attitudes of primary care providers within the ... -
CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells.
(Carcinogenesis, 2009-05)Human prostate cancer (PCa) and prostate epithelial cells predominantly express estrogen receptor (ER) beta, but not ERalpha. ERbeta might utilize various ER coregulators to mediate the E2-signaling pathway in PCa. Here, ... -
Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells.
(Bioorganic & medicinal chemistry letters, 2011-09)Most clinically approved biomarkers of cancer are glycoproteins, and those residing on the cell surface are of particular interest in biotherapeutics. We report a method for selective labeling, affinity enrichment, ... -
Contemporary results of focal therapy for prostate cancer using cryoablation.
(J Endourol, 2010-05)The concept of focal therapy is rapidly evolving and gaining popularity from both physician and patient perspectives. We review the rationale, candidate selection, and results of the first clinical studies of focal cryoablation ... -
Copper signaling axis as a target for prostate cancer therapeutics.
(Cancer Res, 2014-10-15)Previously published reports indicate that serum copper levels are elevated in patients with prostate cancer and that increased copper uptake can be used as a means to image prostate tumors. It is unclear, however, to what ... -
Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism.
(Nature communications, 2018-01-15)The mitogen-activated protein kinase (MAPK) pathway is frequently aberrantly activated in advanced cancers, including metastatic prostate cancer (CaP). However, activating mutations or gene rearrangements among MAPK signaling ... -
Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.
(Clin Cancer Res, 2015-10-15)Notch signaling is implicated in prostate cancer progression and docetaxel resistance. Cui and colleagues describe the additive efficacy and mechanisms of a γ-secretase inhibitor, PF-03084014, and docetaxel in preclinical ... -
Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.
(Prostate Cancer Prostatic Dis, 2016-03)BACKGROUND: Given the potential importance of epithelial plasticity (EP) to cancer metastasis, we sought to investigate biomarkers related to EP in men with localized prostate cancer (PC) for the association with time to ... -
Focal therapy in prostate cancer-report from a consensus panel.
(J Endourol, 2010-05)PURPOSE: To establish a consensus in relation to case selection, conduct of therapy, and outcomes that are associated with focal therapy for men with localized prostate cancer. MATERIAL AND METHODS: Urologic surgeons, radiation ... -
Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.
(Prostate Cancer Prostatic Dis, 2015-12)BACKGROUND: Telomere-related genes play an important role in carcinogenesis and progression of prostate cancer (PCa). It is not fully understood whether genetic variations in telomere-related genes are associated with development ... -
High Dimensional Variable Selection with Error Control.
(Biomed Res Int, 2016)Background. The iterative sure independence screening (ISIS) is a popular method in selecting important variables while maintaining most of the informative variables relevant to the outcome in high throughput data. However, ... -
Hormone naïve prostate cancer: predicting and maximizing response intervals.
(Asian journal of andrology, 2015-11)Hormone naïve advanced prostate cancer is subdivided into two disease states: biochemical recurrence and traditional M1 (metastatic) prostate cancer and characterized by no prior hormonal therapy or androgen deprivation ... -
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.
(World J Urol, 2012-04)OBJECTIVES: To compare the predictive performance and potential clinical usefulness of risk calculators of the European Randomized Study of Screening for Prostate Cancer (ERSPC RC) with and without information on prostate ... -
Knowledge-based IMRT treatment planning for prostate cancer.
(2011)The goal of intensity-modulated radiation therapy (IMRT) treatment plan optimization is to produce a cumulative dose distribution that satisfies both the dose prescription and the normal tissue dose constraints. The typical ... -
Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells.
(Cancer Biol Ther, 2010-01)We have previously shown that treatment of prostate cancer and melanoma cells expressing GRP78 on their cell surface with antibody directed against the COOH-terminal domain of GRP78 upregulates and activates p53 causing ... -
Loss of LDAH associated with prostate cancer and hearing loss.
(Human molecular genetics, 2018-12)Great strides in gene discovery have been made using a multitude of methods to associate phenotypes with genetic variants, but there still remains a substantial gap between observed symptoms and identified genetic defects. ...
